Canison® (Tablets, Solution, Cream) Instructions for Use
ATC Code
G01AF02 (Clotrimazole)
Active Substance
Clotrimazole (Rec.INN registered by WHO)
Clinical-Pharmacological Group
A drug with antifungal action for topical use in gynecology
Pharmacotherapeutic Group
Antifungal agent
Pharmacological Action
A broad-spectrum antifungal agent for vaginal use. The action of clotrimazole is associated with the disruption of ergosterol synthesis, which is a component of the fungal cell membrane, this alters the permeability of the cytoplasmic membrane and causes subsequent cell lysis.
In low concentrations, it acts fungistatically; in high concentrations, it acts fungicidally, and not only on proliferating cells. In fungicidal concentrations, it interacts with mitochondrial and peroxidase enzymes, resulting in an increase in the concentration of hydrogen peroxide to a toxic level, which also contributes to the destruction of fungal cells.
Clotrimazole exhibits fungicidal and fungistatic activity against dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis), yeast-like and mold fungi (Candida spp., including Candida albicans; Torulopsis glabrata, genus Rhodotorula, Pityrosporum orbiculare).
It is active against the causative agent of tinea versicolor – Pityrosporum orbiculare (Malassezia furfur). It is effective against gram-positive bacteria – the causative agent of erythrasma Corynebacterium minutissimum, as well as Staphylococcus spp., Streptococcus spp., gram-negative bacteria – Bacteroides, Gardnerella vaginalis. In high concentrations, it is active against Trichomonas vaginalis.
It does not affect lactobacilli. Primarily resistant variants of sensitive fungi are very rare; the development of secondary resistance in sensitive fungi is also noted in exceptional cases under therapeutic conditions.
Pharmacokinetics
When clotrimazole is applied intravaginally, absorption is 3-10% of the administered dose. High concentrations in vaginal secretion and low concentrations in the blood persist for 48-72 hours.
It is metabolized in the liver to inactive metabolites, which are excreted from the body by the kidneys and through the intestines.
Indications
Genital infections caused by yeast-like fungi of the genus Candida (candidal vulvovaginitis); sanitation of the birth canal before childbirth.
ICD codes
| ICD-10 code | Indication |
| B37.3 | Candidiasis of vulva and vagina |
| N77.1 | Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| 1F23.10 | Candidiasis of vulva and vagina |
| 1F65 | Enterobiasis |
| 1H0Z | Unspecified infection |
| QB9A | Preparatory procedures for subsequent treatment |
| 1A94.0 | Genital or urogenital tract infection caused by Herpes simplex virus |
| GA41 | Ulcerative or erosive diseases of vulva |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Solution, Cream
The dose, method, and regimen of administration are determined individually, depending on the indications, the patient’s age, and the dosage form used.
For external use, the duration of treatment depends on the severity of the disease, the localization of pathological changes, and the effectiveness of therapy.
It is necessary to strictly adhere to the correspondence between the indications and the dosage form used.
Tablets
The dose, method, and regimen of administration are determined individually, depending on the indications, the patient’s age, and the dosage form used.
For topical application, the recommended duration of therapy is 6 days.
It is necessary to strictly adhere to the correspondence between the indications and the dosage form used.
Adverse Reactions
Immune system disorders: allergic reactions, including urticaria, shortness of breath, arterial hypotension, fainting.
Gastrointestinal disorders frequency unknown – abdominal pain.
Renal and urinary disorders frequency unknown – frequent urination, intercurrent cystitis.
Reproductive system and breast disorders frequency unknown – itching, burning, hyperemia and swelling of the vaginal mucosa, ulceration of the vaginal mucosa, rash, pelvic pain, burning sensation in the penis of the sexual partner, pain during sexual intercourse.
Other frequency unknown – headache.
Contraindications
Hypersensitivity to clotrimazole; first trimester of pregnancy, menstruation period.
Use in Pregnancy and Lactation
Use is contraindicated in the first trimester of pregnancy. Use in the second and third trimesters of pregnancy is possible only in cases where the intended benefit to the mother outweighs the potential risk to the fetus.
If it is necessary to use during lactation, the issue of discontinuing breastfeeding should be decided.
Use in Hepatic Impairment
In patients with hepatic insufficiency, the functional state of the liver should be periodically monitored.
Pediatric Use
It can be used in children according to indications, in age-appropriate recommended doses and dosage forms. It is necessary to strictly follow the instructions in the instructions for clotrimazole drugs regarding the use of specific dosage forms of clotrimazole in children of different ages and regarding contraindications for specific age groups in this category of patients.
Special Precautions
If allergic reactions or irritation occur at the site of application of the product, treatment should be discontinued.
To prevent reinfection, hygiene rules should be observed.
It is not recommended to apply clotrimazole to the skin in the eye area.
If clinical signs of infection persist after completion of treatment, a repeat microbiological examination should be performed to confirm the diagnosis.
To prevent infection/reinfection with genital infections, simultaneous treatment of sexual partners is necessary. During treatment, it is recommended to refrain from sexual intercourse.
When using dosage forms intended for topical intravaginal application, it is recommended to use reliable means of contraception. The risk of condom or diaphragm rupture increases with their simultaneous use with clotrimazole.
Drug Interactions
With simultaneous use with amphotericin B, nystatin, the activity of clotrimazole decreases.
Simultaneous intravaginal use of clotrimazole and oral tacrolimus, sirolimus may lead to an increase in the plasma concentration of the latter, so patients should be monitored for symptoms of overdose, if necessary, with measurement of plasma concentrations.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Solution for external use 1%: fl. 20 ml
Marketing Authorization Holder
Agio Pharmaceuticals, Ltd. (India)
Dosage Form
| Canison® | Solution for external use 1%: fl. 20 ml |
Dosage Form, Packaging, and Composition
Solution for external use transparent, colorless.
| 1 ml | |
| Clotrimazole | 10 mg |
Excipients : propylene glycol – up to 1 ml.
20 ml – polyethylene bottles (1) – cardboard packs.
Cream for external use 1%: bottle 20 ml
Marketing Authorization Holder
Agio Pharmaceuticals, Ltd. (India)
Dosage Form
| Canison® | Cream for external use 1%: bottle 20 ml |
Dosage Form, Packaging, and Composition
| Cream for external use 1% | 1 g |
| Clotrimazole | 10 mg |
20 g – aluminum tubes (1) – cardboard packs.
Vaginal tablets 100 mg: 6 pcs.
Marketing Authorization Holder
Agio Pharmaceuticals, Ltd. (India)
Dosage Form
| Canison® | Vaginal tablets 100 mg: 6 pcs. |
Dosage Form, Packaging, and Composition
| Vaginal tablets | 1 tab. |
| Clotrimazole | 100 mg |
Excipients : lactose monohydrate – 615 mg, corn starch – 226.6 mg, gelatin – 3.4 mg, magnesium stearate – 5 mg, microcrystalline cellulose – 25 mg, colloidal silicon dioxide – 15 mg, sodium propylparaben – 0.33 mg, sodium methylparaben – 1.67 mg, purified water – up to 992 mg.
6 pcs. – aluminum strips (1) complete with applicator – cardboard packs.
